450 related articles for article (PubMed ID: 18442018)
21. Refining the multiple protein structure pharmacophore method: consistency across three independent HIV-1 protease models.
Meagher KL; Lerner MG; Carlson HA
J Med Chem; 2006 Jun; 49(12):3478-84. PubMed ID: 16759090
[TBL] [Abstract][Full Text] [Related]
22. Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors.
Wichapong K; Lindner M; Pianwanit S; Kokpol S; Sippl W
Eur J Med Chem; 2009 Apr; 44(4):1383-95. PubMed ID: 18976834
[TBL] [Abstract][Full Text] [Related]
23. Exploring molecular shape analysis of styrylquinoline derivatives as HIV-1 integrase inhibitors.
Leonard JT; Roy K
Eur J Med Chem; 2008 Jan; 43(1):81-92. PubMed ID: 17452064
[TBL] [Abstract][Full Text] [Related]
24. Revealing interaction mode between HIV-1 protease and mannitol analog inhibitor.
Yan GW; Chen Y; Li Y; Chen HF
Chem Biol Drug Des; 2012 Jun; 79(6):916-25. PubMed ID: 22296911
[TBL] [Abstract][Full Text] [Related]
25. 3D-QSAR studies of farnesyltransferase inhibitors: a comparative molecular field analysis approach.
Puntambekar D; Giridhar R; Yadav MR
Bioorg Med Chem Lett; 2006 Apr; 16(7):1821-7. PubMed ID: 16455255
[TBL] [Abstract][Full Text] [Related]
26. 3D-QSAR and molecular docking studies of selective agonists for the thyroid hormone receptor beta.
Du J; Qin J; Liu H; Yao X
J Mol Graph Model; 2008 Sep; 27(2):95-104. PubMed ID: 18436460
[TBL] [Abstract][Full Text] [Related]
27. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
[TBL] [Abstract][Full Text] [Related]
28. Binding orientations, QSAR, and molecular design of thiophene derivative inhibitors.
Liao SY; Chen TJ; Miao TF; Qian L; Zheng KC
Chem Biol Drug Des; 2009 Sep; 74(3):289-96. PubMed ID: 19703031
[TBL] [Abstract][Full Text] [Related]
29. Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking.
Ravindra GK; Achaiah G; Sastry GN
Eur J Med Chem; 2008 Apr; 43(4):830-8. PubMed ID: 17706839
[TBL] [Abstract][Full Text] [Related]
30. Predictive QSAR modeling of HIV reverse transcriptase inhibitor TIBO derivatives.
Mandal AS; Roy K
Eur J Med Chem; 2009 Apr; 44(4):1509-24. PubMed ID: 18760864
[TBL] [Abstract][Full Text] [Related]
31. Molecular modeling studies of pyridopurinone derivatives--potential phosphodiesterase 5 inhibitors.
Srivani P; Srinivas E; Raghu R; Sastry GN
J Mol Graph Model; 2007 Jul; 26(1):378-90. PubMed ID: 17307372
[TBL] [Abstract][Full Text] [Related]
32. Selectivity criterion for pyrazolo[3,4-b]pyrid[az]ine derivatives as GSK-3 inhibitors: CoMFA and molecular docking studies.
Patel DS; Bharatam PV
Eur J Med Chem; 2008 May; 43(5):949-57. PubMed ID: 17707953
[TBL] [Abstract][Full Text] [Related]
33. Molecular modeling studies of N-substituted pyrrole derivatives--potential HIV-1 gp41 inhibitors.
Teixeira C; Barbault F; Rebehmed J; Liu K; Xie L; Lu H; Jiang S; Fan B; Maurel F
Bioorg Med Chem; 2008 Mar; 16(6):3039-48. PubMed ID: 18226912
[TBL] [Abstract][Full Text] [Related]
34. Comparative binding energy analysis of HIV-1 protease inhibitors: incorporation of solvent effects and validation as a powerful tool in receptor-based drug design.
Pérez C; Pastor M; Ortiz AR; Gago F
J Med Chem; 1998 Mar; 41(6):836-52. PubMed ID: 9526559
[TBL] [Abstract][Full Text] [Related]
35. Three-dimensional QSAR analyses of 1,3,4-trisubstituted pyrrolidine-based CCR5 receptor inhibitors.
Zhuo Y; Kong R; Cong XJ; Chen WZ; Wang CX
Eur J Med Chem; 2008 Dec; 43(12):2724-34. PubMed ID: 18538451
[TBL] [Abstract][Full Text] [Related]
36. A priori molecular descriptors in QSAR: a case of HIV-1 protease inhibitors. II. Molecular graphics and modeling.
Kiralj R; Ferreira MM
J Mol Graph Model; 2003 Jun; 21(6):499-515. PubMed ID: 12676237
[TBL] [Abstract][Full Text] [Related]
37. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
[TBL] [Abstract][Full Text] [Related]
38. Docking-based 3D-QSAR study for 11beta-HSD1 inhibitors.
Lee JH; Kang NS; Yoo SE
Bioorg Med Chem Lett; 2008 Apr; 18(7):2479-90. PubMed ID: 18314331
[TBL] [Abstract][Full Text] [Related]
39. Structure-based 3D-QSAR studies on heteroarylpiperazine derivatives as 5-HT3 receptor antagonists.
Zhou YJ; Zhu LP; Tang Y; Ye DY
Eur J Med Chem; 2007 Jul; 42(7):977-84. PubMed ID: 17331624
[TBL] [Abstract][Full Text] [Related]
40. QSAR analyses of 3-(4-benzylpiperidin-1-yl)-N-phenylpropylamine derivatives as potent CCR5 antagonists.
Roy K; Leonard JT
J Chem Inf Model; 2005; 45(5):1352-68. PubMed ID: 16180912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
